Welcome to our dedicated page for Imac Hldgs news (Ticker: BACK), a resource for investors and traders seeking the latest updates and insights on Imac Hldgs stock.
News and filings for IMAC Holdings, Inc. (BACK) highlight a company pivoting toward precision oncology through its subsidiary Ignite Proteomics LLC. Recent announcements describe the launch of Ignite, the transfer of a key Proprietary Laboratory Analyses (PLA) code for a proteomic breast cancer assay, and multiple clinical and research collaborations that showcase how the company applies Reverse Phase Protein Array (RPPA) technology to guide cancer treatment decisions.
Investors and healthcare observers following BACK news will encounter updates on Ignite’s CLIA‑certified and CAP‑accredited laboratory operations, as well as data presentations and peer‑reviewed publications. These include a case study in npj Precision Oncology demonstrating a complete response in metastatic triple‑negative breast cancer guided by proteomic analysis, and a British Journal of Cancer paper on functional activation of the AKT–mTOR signaling axis as a predictor of therapy response.
Company news also covers collaborations with institutions such as Inova Health and Vanderbilt University Medical Center. These projects involve profiling tumor and immune‑signaling pathways in gastrointestinal and breast cancers, using RPPA‑based assays to generate biomarker data for molecular tumor boards and immuno‑oncology research teams. Additional releases discuss the completed transfer of PLA code 0249U to Ignite Proteomics, positioning the assay within the Medicare Clinical Laboratory Fee Schedule and MolDx guidance.
Alongside scientific and clinical milestones, the news flow for IMAC Holdings includes Nasdaq notifications related to delayed Form 10‑Q filings and extensions to regain compliance with listing rules. By reviewing this news stream, readers can see how IMAC combines regulatory developments, financing disclosures, and proteomics‑focused clinical progress as it advances its stated goal of improving patient outcomes and personalized cancer care.
IMAC Holdings announced a registered direct offering to institutional investors for 5,164,474 shares at $0.76 per share, expected to close by August 16, 2022. This offering, along with a concurrent private placement, is projected to generate approximately $3.9 million before expenses. The firm will use these proceeds for working capital and strategic activities. Additionally, the investors will receive Series 1 and Series 2 warrants to purchase the same number of shares at an exercise price of $0.95, exercisable six months post-issuance.
IMAC Holdings, Inc. (BACK) has announced a price increase for its chiropractic and Performance Zone memberships at The BackSpace, effective August 2022. The monthly membership fee for chiropractic care has risen by $7 to $72, while individual chiropractic adjustments remain at $25. The newly introduced Performance Zone offers stretching services, aimed at enhancing musculoskeletal health through various techniques. Individual stretching sessions are priced at $35, with the initiative expected to expand the customer base without incurring significant additional costs.